Sagimet Biosciences (NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors, reported its fourth-quarter and full-year 2025 financial results on Wednesday.
The company highlighted a robust liquidity position and significant clinical momentum, specifically within its metabolic dysfunction-associated steatohepatitis (MASH) and dermatology franchises.
Sagimet ended the year with a cash balance of $113.1 million, providing a substantial runway to fund its upcoming clinical catalysts.
A major highlight of the year was the successful completion of a Phase 1 pharmacokinetic (PK) trial evaluating the co-administration of denifanstat, the company’s lead FASN inhibitor, with resmetirom.
The study reported no significant safety signals, clearing a critical path for potential combination therapies.
To further solidify this strategy, the company secured an exclusive global license to TAPI resmetirom API.
In the dermatology sector, Sagimet reached a major regulatory milestone in China.
The National Medical Products Administration (NMPA) accepted a New Drug Application (NDA) for denifanstat for the treatment of acne.